Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (1297)	7/3/2000 12:53:35 AM
From: Torben Noerup Nielsen	Respond to of 52153

Peter, Somehow I thought that NBIX was in pivotal trials this year, but I haven't kept up all that well. How about NRGN? Thanks, Torben

To: Biomaven who wrote (1297)	7/3/2000 2:50:10 AM
From: Miljenko Zuanic	Read Replies (2) \| Respond to of 52153

Peter, <<Further, the FDA will be tougher (and hence slower) on a "new" new drug than on an "old" new drug.>> Why? NBIX candidate is Sonata sister (in theory) and (+)-Zopiclone is single enantiomer of the racemate, which never win FDA blessing. So, for FDA NBI34060 is “old” new (or me too) and (+)-Zopiclone is “new” new. Both candidates will need one year safety data and 6 months large pivotal data. SEPR have small lead (4-6 months), but clinical data will dictate market success. Somehow, I have gut-filing that NBI34060 is bit more than simple non-benzodiazepine hypnotic. Miljenko